Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is in a strong position to continue its growth trajectory in the generic drug market, as it maintains a significant presence in North America, Europe, Japan, Russia, and Israel. The recent acquisition of Emalex strengthens Teva's portfolio with a first-in-class asset targeting the pediatric Tourette population. The company is focused on developing innovative medicines and has a pipeline of potential treatments in neurology and immunology. With its strong financials and strategic initiatives in place, Teva has the potential for significant growth and impact in the pharmaceutical industry.

Bears say

Teva Pharmaceutical Indus is facing several challenges that may hinder its future growth prospects. The recent order to delist five patents for its ProAir HFA inhaler device could result in increased competition from generic versions, while its acquisition of businesses and ongoing legal issues could add further financial strain. Additionally, although Teva's innovative portfolio has shown strong performance, there is uncertainty surrounding regulation and pricing policies that could impact its margins and earnings.

Teva Pharmaceutical (TEVA) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Buy based on their latest research and market trends.

According to 10 analysts, Teva Pharmaceutical (TEVA) has a Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.